Physician profile
Mark A Miller
NPI 1508894585
$17,302.41
in general payments reported to CMS, 2019-2025
30 companies · $3,368 in 2025
The $3,368 reported for 2025 was more than what 81% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $1,814 · 2021: $2,483 · 2022: $2,255 · 2023: $2,367 · 2024: $2,499 · 2025: $3,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,083 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,083.15 |
| Education | $151.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,817.69 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $3,545.72 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,812.88 | 2019-2025 | Dupixent |
| Csl Behring | $1,641.44 | 2019-2025 | Haegarda, Kcentra, Andembry |
| Genzyme Corporation | $903.70 | 2019-2025 | |
| Genentech USA, INC. | $647.53 | 2019-2025 | Xolair |
| Optinose US, INC. | $609.89 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $585.26 | 2021-2025 | Orladeyo, Orladeyo |
| Covis Pharma Gmbh | $438.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.54 | 2019-2023 | Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $412.93 | 2020-2025 | Takhzyro, Cuvitru |
| Kaleo, INC. | $394.72 | 2019-2024 | Auvi-Q |
| Amgen INC. | $301.57 | 2021-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $291.92 | 2025 | Neffy |
| Pfizer INC. | $289.80 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $274.96 | 2021-2025 | |
| Pharming Healthcare, INC. | $180.18 | 2019-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $152.82 | 2019-2021 | |
| Shire North American Group INC | $88.99 | 2019 | |
| Blueprint Medicines Corporation | $76.44 | 2024 | Ayvakit |
| Stryker Corporation | $61.11 | 2025 | 1788 |
| Alk-Abello, INC | $58.70 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $54.13 | 2024-2025 | Sajazir |
| Ionis Pharmaceuticals, INC. | $50.02 | 2025 | Dawnzera |
| Hikma Pharmaceuticals USA | $44.84 | 2024-2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $44.76 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $38.29 | 2021-2022 | |
| Uswm, LLC | $25.00 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $20.22 | 2020 | |
| Abbvie INC. | $12.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.